Utility of the HandScan in monitoring disease activity and prediction of clinical response in rheumatoid arthritis patients: an explorative study
- PMID: 33693304
- PMCID: PMC7931797
- DOI: 10.1093/rap/rkab004
Utility of the HandScan in monitoring disease activity and prediction of clinical response in rheumatoid arthritis patients: an explorative study
Abstract
Objectives: The aims were to determine the ability of the HandScan [assessing inflammation in hand and wrist joints using optical spectral transmission (OST)] to measure RA disease activity longitudinally, compared with DAS28, and to determine whether short-term (i.e. 1 month) changes in the OST score can predict treatment response at 3 or 6 months.
Methods: Participants visited the outpatient clinic before the start of (additional) RA medication and 1, 3 and 6 months thereafter. Disease activity was monitored at each visit with the HandScan and DAS28 in parallel. A mixed effects model with DAS28 as the outcome variable with a random intercept at patient level, visit month and DAS28 one visit earlier was used to evaluate whether changes in the OST score are related to changes in DAS28. Binary logistic regression was used to test the predictive value of short-term changes in the OST score together with the baseline OST score for achievement of treatment response (EULAR or ACR criteria). All models were adjusted for RA stage (early or established).
Results: In total, 64 RA patients were included. One unit change in OST score was found to be related to an average DAS28 change of 0.03 (95% CI: 0.01, 0.06, P = 0.03). When adding OST score as a variable in the longitudinal model, the ability of the model to estimate DAS28 (i.e. explained variance) increased by 2%, to 59%. Neither baseline OST score nor short-term change in OST score was predictive for treatment response at 3 or 6 months.
Conclusion: A longitudinal association of OST score with DAS28 exists, although explained variance is low. The predictive ability of short-term changes in HandScan for treatment response is limited.
Keywords: DMARDs; biological; disease activity; inflammation; optical spectral transmission; rheumatoid arthritis.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Figures


Similar articles
-
Increased predictive value of optical spectral transmission in early rheumatoid arthritis through use of patient-adjusted cut-off scores.Arthritis Res Ther. 2024 Sep 20;26(1):165. doi: 10.1186/s13075-024-03400-y. Arthritis Res Ther. 2024. PMID: 39304933 Free PMC article.
-
Optical imaging (HandScan) can identify ultrasound remission in rheumatoid arthritis.BMC Musculoskelet Disord. 2024 May 7;25(1):361. doi: 10.1186/s12891-024-07472-4. BMC Musculoskelet Disord. 2024. PMID: 38714989 Free PMC article.
-
Development and Validation of Rheumatoid Arthritis Disease Activity Indices Including HandScan (Optical Spectral Transmission) Scores.Arthritis Care Res (Hoboken). 2022 Sep;74(9):1493-1499. doi: 10.1002/acr.24607. Epub 2022 Jun 18. Arthritis Care Res (Hoboken). 2022. PMID: 33770421 Free PMC article.
-
Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort.Rheumatology (Oxford). 2014 Jun;53(6):1075-86. doi: 10.1093/rheumatology/ket449. Rheumatology (Oxford). 2014. PMID: 24501240 Review.
-
The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis.Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S40-S44. Epub 2016 Oct 18. Clin Exp Rheumatol. 2016. PMID: 27762189 Review.
Cited by
-
Increased predictive value of optical spectral transmission in early rheumatoid arthritis through use of patient-adjusted cut-off scores.Arthritis Res Ther. 2024 Sep 20;26(1):165. doi: 10.1186/s13075-024-03400-y. Arthritis Res Ther. 2024. PMID: 39304933 Free PMC article.
-
Optical imaging (HandScan) can identify ultrasound remission in rheumatoid arthritis.BMC Musculoskelet Disord. 2024 May 7;25(1):361. doi: 10.1186/s12891-024-07472-4. BMC Musculoskelet Disord. 2024. PMID: 38714989 Free PMC article.
-
Optical spectral transmission to assess glucocorticoid therapy response in patients with arthritis: a longitudinal follow-up comparison with joint ultrasound.Arthritis Res Ther. 2023 Mar 25;25(1):47. doi: 10.1186/s13075-023-03023-9. Arthritis Res Ther. 2023. PMID: 36964628 Free PMC article. Clinical Trial.
-
Diagnostic performance of optical spectral transmission compared to magnetic resonance imaging in patients with inflammatory arthritis.Arthritis Res Ther. 2025 Jan 30;27(1):17. doi: 10.1186/s13075-025-03478-y. Arthritis Res Ther. 2025. PMID: 39885525 Free PMC article.
References
-
- Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023–38. - PubMed
-
- Smolen JS, Landewé R, Bijlsma J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685–99. - PubMed
-
- Bakker MF, Jacobs JW, Welsing PM. et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012;156:329–38. - PubMed
-
- Meier AJL, Rensen WHJ, de Box PK, de Nijs RNJ. Potential of optical spectral transmission measurements for joint inflammation measurements in rheumatoid arthritis patients. J Biomed Opt 2012;17:081420. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources